Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 26, 2025, titled "CuraTeQ Biologics s.r.o, a wholly owned step-down subsidiary of the Company, receives Positive Opinion from CHMP for Dazublys?, a Trastuzumab Biosimilar".